Indacaterol Indacaterol
Milestones in Drug Therapy

Indacaterol

The First Once-daily Long-acting Beta2 Agonist for COPD

    • $84.99
    • $84.99

Publisher Description

Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available.

This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled β2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.

GENRE
Professional & Technical
RELEASED
2013
November 19
LANGUAGE
EN
English
LENGTH
153
Pages
PUBLISHER
Springer Basel
SELLER
Springer Nature B.V.
SIZE
2
MB

Other Books in This Series

Cannabinoids as Therapeutics Cannabinoids as Therapeutics
2006
Bipolar Depression: Molecular Neurobiology, Clinical Diagnosis and Pharmacotherapy Bipolar Depression: Molecular Neurobiology, Clinical Diagnosis and Pharmacotherapy
2009
Bipolar Depression: Molecular Neurobiology, Clinical Diagnosis, and Pharmacotherapy Bipolar Depression: Molecular Neurobiology, Clinical Diagnosis, and Pharmacotherapy
2017
Gene Therapy for Autoimmune and Inflammatory Diseases Gene Therapy for Autoimmune and Inflammatory Diseases
2011
Glutamate-based Therapies for Psychiatric Disorders Glutamate-based Therapies for Psychiatric Disorders
2010
Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins
2017